Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM


Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM
Slides from presentations at ASCO 2011 and comments from Sergio Giralt, MD

Boccadoro M et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial. Proc ASCO 2011;Abstract 8020.

Dr Giralt is Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center in New York, New York.